Arcus Biosciences (NYSE:RCUS) Shares Down 6.9% – Time to Sell?

Posted by George Bondi on Jun 10th, 2026

Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report)’s stock price traded down 6.9% during trading on Wednesday . The company traded as low as $22.12 and last traded at $22.0080. 290,485 shares traded hands during mid-day trading, a decline of 75% from the average session volume of 1,182,166 shares. The stock had previously closed at $23.64.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. The Goldman Sachs Group upped their price target on Arcus Biosciences from $30.00 to $34.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of Arcus Biosciences in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Monday, April 20th. Truist Financial assumed coverage on Arcus Biosciences in a research report on Monday, May 18th. They set a “buy” rating and a $35.00 price target on the stock. Finally, Leerink Partners set a $47.00 price target on Arcus Biosciences in a research report on Monday, April 20th. Eight investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $35.10.

View Our Latest Analysis on RCUS

Arcus Biosciences Stock Down 3.2%

The stock has a market capitalization of $2.88 billion, a PE ratio of -7.21 and a beta of 0.85. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.04 and a quick ratio of 4.04. The business’s fifty day moving average price is $23.94 and its two-hundred day moving average price is $22.89.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). The company had revenue of $17.00 million for the quarter, compared to analysts’ expectations of $29.49 million. Arcus Biosciences had a negative net margin of 156.36% and a negative return on equity of 68.97%. Arcus Biosciences’s quarterly revenue was down 39.3% compared to the same quarter last year. During the same period last year, the firm earned ($1.14) earnings per share. On average, equities research analysts forecast that Arcus Biosciences, Inc. will post -3.61 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Robert C. Goeltz II sold 7,763 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $25.63, for a total transaction of $198,965.69. Following the sale, the chief financial officer directly owned 84,161 shares of the company’s stock, valued at $2,157,046.43. The trade was a 8.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Alexander Azoy sold 2,562 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $25.77, for a total transaction of $66,022.74. Following the sale, the chief accounting officer directly owned 39,581 shares in the company, valued at $1,020,002.37. This trade represents a 6.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Arcus Biosciences

A number of large investors have recently made changes to their positions in the stock. California State Teachers Retirement System grew its holdings in shares of Arcus Biosciences by 16.7% during the first quarter. California State Teachers Retirement System now owns 105,776 shares of the company’s stock valued at $2,285,000 after buying an additional 15,110 shares during the last quarter. Royal Bank of Canada boosted its holdings in Arcus Biosciences by 14.6% in the first quarter. Royal Bank of Canada now owns 4,758 shares of the company’s stock valued at $102,000 after purchasing an additional 607 shares during the last quarter. Quantinno Capital Management LP boosted its holdings in Arcus Biosciences by 8.5% in the first quarter. Quantinno Capital Management LP now owns 17,295 shares of the company’s stock valued at $374,000 after purchasing an additional 1,349 shares during the last quarter. SummitTX Capital L.P. boosted its holdings in Arcus Biosciences by 17.4% in the first quarter. SummitTX Capital L.P. now owns 34,219 shares of the company’s stock valued at $739,000 after purchasing an additional 5,076 shares during the last quarter. Finally, Entropy Technologies LP purchased a new stake in Arcus Biosciences in the first quarter valued at $294,000. 92.89% of the stock is owned by hedge funds and other institutional investors.

About Arcus Biosciences

(Get Free Report)

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.